GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • BMJ  (14)
Material
Publisher
  • BMJ  (14)
Person/Organisation
Language
Years
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two : National Harbor, MD, USA. 9-13 November 2016
    BMJ ; 2016
    In:  Journal for ImmunoTherapy of Cancer Vol. 4, No. S1 ( 2016-11)
    Details
    In: Journal for ImmunoTherapy of Cancer, BMJ, Vol. 4, No. S1 ( 2016-11)
    Type of Medium: Online Resource
    ISSN: 2051-1426
    URL: Article
    DOI: 10.1186/s40425-016-0173-6
    Language: English
    Publisher: BMJ
    Publication Date: 2016
    detail.hit.zdb_id: 2719863-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    A genomewide scan for quantitative trait loci underlying areal bone size variation in 451 Caucasian families
    BMJ ; 2006
    In:  Journal of Medical Genetics Vol. 43, No. 11 ( 2006-11-01), p. 873-880
    Details
    In: Journal of Medical Genetics, BMJ, Vol. 43, No. 11 ( 2006-11-01), p. 873-880
    Type of Medium: Online Resource
    ISSN: 1468-6244
    URL: Article
    DOI: 10.1136/jmg.2006.041251
    Language: English
    Publisher: BMJ
    Publication Date: 2006
    detail.hit.zdb_id: 2009590-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    POS0315 DIAGNOSTIC PERFORMANCE OF CASPAR CRITERIA FOR PSORIATIC ARTHRITIS WITH OR WITHOUT INTEGRATION OF ULTRASOUND
    BMJ ; 2022
    In:  Annals of the Rheumatic Diseases Vol. 81, No. Suppl 1 ( 2022-06), p. 408-409
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 81, No. Suppl 1 ( 2022-06), p. 408-409
    Abstract: Although the CASPAR criteria in the diagnosis of psoriatic arthritis (PsA) have been validated, CASPAR based on physical examination (PE) is not “gold standard”. The ultrasound (US) could improve the diagnostic accuracy as compared to clinical examination alone. Objectives To evaluate the diagnostic performance of CASPAR criteria for psoriatic arthritis (PsA) with or without integration of ultrasound (US). Methods The patients with hint of PsA were enrolled. Tender and swollen joint counts, presents of enthesitis and dactylitis were collected by physical examination (PE). US was performed to evaluate peripheral joints, entheses and tendons. The additional value of US to CASPAR criteria were analysed. Results 326 consecutive patients were enrolled, with 164 PsA and 162 non-PsA. Significantly higher frequencies of tenosynovitis and enthesitis on US and new bone formation on X-ray were found in PsA than non-PsA patients (56.7% vs. 13.0%; 62.2% vs. 14.2%; 62.2% vs . 8.0%, p 〈 0.01 for all). Logistic regression analysis showed that dactylitis (OR=12.0, p 〈 0.01), family history of PsO/PsA (OR=3.1, p 〈 0.05), nail involvement (OR=3.5, p= 0.01), new bone formation (OR=14.8, p 〈 0.01) and tenosynovitis on US (OR=21.3, p 〈 0.01), enthesitis on US (OR=21.7, p 〈 0.01) were independent risk factors for PsA. Adding US tenosynovitis and/or enthesitis to CASPAR criteria showed better performance by improving the specificity (91.4% vs. 67.9%) and meanwhile keeping sensitivity (92.1% vs. 96.3%). When replacing hand X-ray by US in CASPAR criteria, the sensitivity and specificity were comparable to CASPAR criteria adding with US. The diagnostic accuracy was 82.2% for CASPAR criteria based on PE, 91.7% for CASPAR integrated with US, and 91.4% for CASPAR with US to replace X-ray. Conclusion CASPAR criteria based on US improve the diagnosis utility of PsA than CASPAR criteria based on PE. US assessment is valuable in the diagnosis of PsA. References [1]Fiorenza A, Bonitta G, Gerratana E, et al. Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. Clinical and experimental rheumatology 2020;38 Suppl 123:31-9. [2]Zabotti A, Bandinelli F, Batticciotto A, et al. Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. Rheumatology (Oxford) 2017;56:1518-32. Figure 1. ROC curves for adding US or substituting X-ray by US in CASPAR criteria. Receiver operating characteristic (ROC) curve illustrates the diagnosis performance of CASPAR criteria adding US or substituting X-ray by US in CASPAR criteria and CASPAR criteria based on PE alone. The area under the curve of the ROC curve (AUC) was 0.929 (95%CI 0.897, 0.961) (p 〈 0.01) for adding US to CASPAR criteria. AUC was 0.908 (95%CI 0.876, 0.940) (p 〈 0.01) for CASPAR criteria based on PE. And AUC was 0.916 (95%CI 0.880, 0.951) (p 〈 0.01) for substituting X-ray by US in CASPAR criteria. CASPAR: ClASsification criteria for Psoriatic ARthritis; PE: physical examination; US: ultrasound. Disclosure of Interests None declared
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2022-eular.3605
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2022
    detail.hit.zdb_id: 1481557-6
    detail.hit.zdb_id: 7090-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    AB0642 CLINICAL CHARACTERISTICS AND FACTORS ASSOCIATED WITH BONE EROSION IN GOUT PATIENTS WITH TOPHI
    BMJ ; 2021
    In:  Annals of the Rheumatic Diseases Vol. 80, No. Suppl 1 ( 2021-06), p. 1354.2-1354
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 80, No. Suppl 1 ( 2021-06), p. 1354.2-1354
    Abstract: Bone erosion is a frequent complication of gout patients with tophi and can lead to joint damage, deformity and musculoskeletal disability. Few studies have focused on clinical characteristics and factors associated with bone erosion in gout patients with tophi. Objectives: The aim of this study was to describe clinical characteristics of bone erosion in gout patients with tophi. Methods: Bone erosion was detected by X-ray. Gout patients with tophi were divided into bone erosion group and non bone erosion group. The clinical characteristics were recorded. Comparison of clinical characteristics and risk factors for bone erosion were analyzed between two groups. Multivariate logistic regression analysis was conducted. Results: A total of 171 gout patients with tophi were enrolled, 121 patients with bone erosion and 50 patients without bone erosion. Bone erosion group were older, with prolonged duration with gout and tophi, higher levels of serum creatinine, lower levels of glomerular filtration rate (GFR), C-reactive protein and BMI. In univariate regression analysis, age, gout duration, tophi duration, GFR were associated with bone erosion. In multivariable logistic regression analysis, tophi duration was independently associated with bone erosion. Conclusion: Gout patients with bone erosion present different clinical characteristics compared with those without bone erosion. Tophi duration was strongly associated with bone erosion in patients with gout. Table 1. Comparison of clinical characteristics between bone erosion patients and non bone erosion patients. Non Bone erosion Bone erosion P Value N(male) 50(47) 121(118) 0.255 Age(year) 45.82±14.15 53.74±14.88 0.002 BMI (kg/m2) 26.01±4.58 24.18±4.72 0.027 WBC(10 9 /mL) 9.73±3.40 11.37±13.26 0.404 PLT(10 9 /mL) 329.86±96.22 328.31±124.02 0.938 HGB(g/L) 86.58±63.78 102.75±51.16 0.201 ALT(U/L) 37.74 ±26.56 34.26±35.26 0.561 sUA(umol/L) 540.16±121.79 539.00±121.46 0.962 sCr(umol/L) 111.47±25.26 135.77±52.43 〈 0.001 GFR (ml/min/1.73m 2 ) 74.01±27.94 56.68±22.84 0.003 ESR(mm/h) 61.78±37.32 53.08±36.70 0.181 CRP(mg/L) 60.00±58.26 36.45±42.62 0.014 Gout duration (year) 9.22±5.46 12.63±7.59 0.001 Tophi duration(year) 3.77±3.22 6.64±4.81 0.001 Hypertension, n 17 52 0.277 Diabetes, n 9 12 0.143 Smoking history, n 20 55 0.513 Drinking history, n 14 37 0.737 Ulceration, n 10 35 0.228 Disclosure of Interests: None declared.
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2021-eular.3389
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2021
    detail.hit.zdb_id: 1481557-6
    detail.hit.zdb_id: 7090-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    AB0791 THE DIAGNOSIS VALUE OF SYNOVIAL FLUID LYMPHOCYTE IN GOUT PATIENTS
    BMJ ; 2021
    In:  Annals of the Rheumatic Diseases Vol. 80, No. Suppl 1 ( 2021-06), p. 1421.1-1421
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 80, No. Suppl 1 ( 2021-06), p. 1421.1-1421
    Abstract: Synovial fluid cell counts have long been recognised to have utility in the diagnosis and management of arthritis. Few studies have explained the diagnosis value of synovial fluid cell counts in gout patients. Objectives: The study aims to investigate the diagnosis value of synovial fluid cell counts in gout patients. Methods: A total of 185 gout, 64 rheumatoid arthritis(RA), 26 axial spondyloarthritis(axSpA) and 24 osteoarthritis(OA) patients were included into the study. According to serum uric acid(sUA) level on attack, gout patients were divided into normal sUA gout patients and high sUA gout patients. The laboratory data was recorded and ROC curve was performed. Results: The synovial fluid WBC, PBMC, monocyte, PMN and neutrophil in gout patients were higher than OA patients (P 〈 0.05). The synovial fluid PBMC and lymphocyte in gout patients were lower than RA and axSpA patients (P 〈 0.05). Compared with RA, axSpA and OA patients, ROC curve showed that the AUC value of lymphocyte and sUA for gout were 0.728 and 0.881, which were higher than other variables. The optimal cut off value of lymphocyte for gout was 1.362, with sensitivity of 83.3% and specificity of 60.6%. The AUC value of lymphocyte and sUA for normal sUA gout patients were 0.694 and 0.643, which were higher than other variables. The optimal cut off value of lymphocyte for normal sUA gout patients was 1.362, with sensitivity of 81.6% and specificity of 60.6%. Conclusion: Synovial fluid cell counts of gout patients were different from RA, axSpA, and OA patients. Synovial fluid lymphocyte had a higher diagnosis value for gout. References: [1]Scanu A, Oliviero F, Ramonda R, et al. Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor β1 in the resolution phase. Ann Rheum Dis. 2012, 71(4): 621-4. Table 1. Basic characteristics of the participants Gout(n=185 ) RA(n=64 ) axSpA (n=26 ) OA(n=24 ) P value Age (years ) 48.58±15.58 56.19±12.39 * 32.96±15.19 *# 69.63±12.43 *# & 〈 0.001 Gender (male/female ) 176/9 11/53 21/5 8/16 〈 0.001 WBC(×10 9 /L ) 18.58±22.94 22.24±20.87 15.52±15.03 3.03±5.59 *# & 0.002 PBMC(×10 9 /L ) 1.85±1.99 3.68±2.43 * 3.85±3.34 * 0.74±1.01 *# & 〈 0.001 Monocyte(×10 9 /L ) 1.02±1.59 1.24±1.11 1.34±1.52 0.29±0.37 *# & 0.030 PMN(×10 9 /L ) 16.77±21.51 18.57±19.32 15.75±24.17 2.30±5.00 *# & 0.008 Lymphocyte (×10 9 /L ) 0.80±0.83 2.43±1.76* 2.50±2.04* 0.45±0.80 # & 〈 0.001 Eosinophil (×10 9 /L ) 1.32±3.75 0.56±0.93 0.11±0.17 0.49±1.85 0.098 Neutrophil (×10 9 /L ) 16.42±21.16 18.82±20.89 11.13±14.23 2.23±4.87 *# 0.003 UA(μM ) 497.92±132.24 299.31±97.91 * 351.81±118.93 * 333.38±75.19 * 〈 0.001 ESR(mm/h ) 61.02±37.68 82.42±32.87 * 68.12±36.25 42.34±35.91 *# & 〈 0.001 CRP(mg/L ) 56.52±45.64 44.01±35.27 * 65.49±39.85 # 22.11±40.65 *# & 〈 0.001 * P 〈 0.05 vs gout group, # P 〈 0.05 vs RA group, & P 〈 0.05 vs axSpA group Disclosure of Interests: None declared
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2021-eular.1992
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2021
    detail.hit.zdb_id: 1481557-6
    detail.hit.zdb_id: 7090-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    AB0645 CLINCAL CHARACTERISTICS OF GOUT PATIENTS WITH RENAL CYSTS
    BMJ ; 2021
    In:  Annals of the Rheumatic Diseases Vol. 80, No. Suppl 1 ( 2021-06), p. 1355.2-1356
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 80, No. Suppl 1 ( 2021-06), p. 1355.2-1356
    Abstract: Gout is a crystal-related arthropathy caused by monosodium urate deposition, which is a common and treatable form of inflammatory arthritis and becoming more prevalent[1]. A few studies have found that gout patients have an increased prevalence of simple renal cysts[2, 3] . The relationship between gout and renal cysts is still insufficient. Objectives: Compare the difference between gout with renal cyst and without renal cyst. Methods: We retrospectively collected data on 200 gout patients. The data includes age, gender, uric acid, creatinine, glomerular filtration rate, 24-hour urine collection, and whether they have kidney stones, renal cysts, coronary heart disease, hypertension, and diabetes. Chi-square and exact Fisher’s tests were utilized, while continuous variables were assessed by Student’s t-test. A P value of less than 0.05 was considered statistically significant. Results: Of the 200 gout patients, 56 have kidney cysts(28%). In gout patients who had a renal cyst, were significantly older than patients without renal cysts (59.14 vs. 46.87, P = 0.000), more number of people suffering from coronary heart disease (7 vs. 5, P = 0.016). The glomerular filtration rate was lower (58.5 vs. 71.6, P = 0.000), with lower urinary creatinine, uric acid, and urinary potassium. Conclusion: Gout patients with and without simple renal cysts have significant differences in age, hypertension, cardiovascular disease, GFR, serum creatinine, urine creatinine, and urine potassium. References: [1]N. Dalbeth, T.R. Merriman, L.K. Stamp, Gout, Lancet 388(10055) (2016) 2039-2052. [2]E.M. Hasegawa, R. Fuller, M.C. Chammas, F.M. de Mello, C. Goldenstein-Schainberg, Increased prevalence of simple renal cysts in patients with gout, Rheumatol Int 33(2) (2013) 413-6. [3]Y. Han, M. Zhang, J. Lu, L. Zhang, J. Han, F. Zhao, H. Chen, Y. Bao, W. Jia, Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes, Sci Rep 7(1) (2017) 3802. Table 1. Clinical characteristics of gout patients Renal cyst(n=56) Without Renal cyst(n=144) P Disease duration, (month) 98.7(±64.1) 91.2(±67.0) 0.468 Age, (year) 59.14(±14.3) 46.78(±15.9) 0.000 Gender, n(F/M) 7/49 11/133 0.281 Smoking history, n(%) 18(32.1%) 47(32.6%) 0.946 Drinking history, n(%) 10(17.9%) 32(22.2%) 0.496 Hypertension, n(%) 31(55.3%) 49(34.0%) 0.006 Diabetes, n(%) 9(16.1%) 15(10.4%) 0.269 CVDs, n(%) 7(12.5%) 5(3.4%) 0.016 Nephrolithiasis, n(%) 14(25%) 43(29.9%) 0.494 UA, (μmol/L) 494.8(±158.0) 544.3(±121.0) 0.037 Serum creatinine, (μmol/L) 139.4(±57.2) 116.5(±35.45) 0.007 GFR, (ml/L) 58.5(±22.5) 71.6(±22.3) 0.000 FEUA, (%) 7.0(±3.2) 6.0(±3.2) 0.052 Urine creatinine, (μmol/L) 4687.09(±1832.9) 5565.2(±2599.8) 0.008 Urine Uric acid, (μmol/L) 1204.9(±772.0) 1542.1(±1048.5) 0.030 Urine sodium, (mmol) 132.1(±68.7) 131.2(±76.6) 0.939 Urine potassium, (mmol) 25.6(±12.5) 31.8(±14.2) 0.005 Disclosure of Interests: None declared.
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2021-eular.3702
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2021
    detail.hit.zdb_id: 1481557-6
    detail.hit.zdb_id: 7090-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    AB0050 A NOVEL METHOD FOR ISOLATION OF EXOSOMES FROM SYNOVIAL FLUID
    BMJ ; 2021
    In:  Annals of the Rheumatic Diseases Vol. 80, No. Suppl 1 ( 2021-06), p. 1057.2-1057
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 80, No. Suppl 1 ( 2021-06), p. 1057.2-1057
    Abstract: Exosomes in synovial fluid (SF) has a close relationship with the pathogenesis of rheumatiod arthritis. As a complex biological fluid, SF presents challenges for exosomes isolation using standard methods, such as Exoquick TM kit and ultracentrifugation. Objectives: The study aims to compared the quality of exosomes separated by Exoquick TM kit (TM), Exoquick TM kit+Exoquick TC kit (TM-TC), ultracentrifugation (UC) and TM-TC+UC(TM-TC-UC) from SF. Methods: Exosomes was separated by TM, TM-TC, UC and TM-TC-UC respectively. The size and concentrations of exosomes were detected by high sensitivity flow cytometry for nanoparticle analysis. Total protein and RNA were extracted from exosomes. SDS-PAGE was used to detect the protein distribution of exosomes. Western blot was used to examine the level of albumin and exosomes marker (TSG101 and CD81). Results: There was no statistic difference in the diameters of exosomes separated by the four methods. The concentrations of exosomes in TM, TM-TC, TM-TC-UC and UC were (5.65±0.93), (3.02±1.19), (1.67±0.25) and (4.61±0.73) *10 9 Particles/mL. The protein concentrations of exosomes separated by the four methods were consistent with the concentrations of exosomes. SDS-PAGE showed that the protein distribution of exosomes separated by the four methods were different. Low levels of albumin were detected in TM-TC and TM-TC-UC, while high levels of albumin in TM and UC. Total RNA concentrations from exosomes in TM-TC was higher than other groups. Conclusion: TM-TC can be used to obtain higher quality exosomes from SF for the study of exosome-enriched components. References: [1]Helwa I, et al, A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents. PloS one, 2017. 12(1): p. e0170628-e0170628. Figure 1. A : SDS-PAGE showed the protein distribution of exosomes; B : the detection of albumin, TSG101 and CD81 by western blot. Disclosure of Interests: None declared
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2021-eular.1996
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2021
    detail.hit.zdb_id: 1481557-6
    detail.hit.zdb_id: 7090-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    AB0047 T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN–CONTAINING PROTEIN 3 EXPRESSION IN REGULATORY T CELLS OF ANKYLOSING SPONDYLITIS PATIENTS AND THE CORRELATION WITH DISEASE ACTIVITY
    BMJ ; 2020
    In:  Annals of the Rheumatic Diseases Vol. 79, No. Suppl 1 ( 2020-06), p. 1326.2-1326
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 79, No. Suppl 1 ( 2020-06), p. 1326.2-1326
    Abstract: Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disease. Regulatory T cells have been found in peripheral blood of AS patients. However, there is a controversy regarding the relative number and function of regulatory T cells in AS. T-cell immunoglobulin and mucin domain–containing protein 3 (Tim-3) is a negative immune regulator that participates in immune responses and widely expresses on a variety of immune cells. Many studies have shown that Tim-3 participates in tumors, infections, hematological system diseases and autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, etc). While there has not yet clinical trials with large samples to verify whether or not Tim-3 is involved in the incidence of AS and the relationship between the disease activity of AS and the expression of Tim-3 in regulatory T cells. Objectives: The present study aimed to identify the Tim-3 expression in regulatory T cells in AS patients, and the association between Tim-3 and the disease activity of AS. Methods: There were 47 patients diagnosed as AS and 51 age- and sex-matched healthy controls (HCs) from Guangdong Second Provincial Central Hospital enrolled in the study. The clinical information of the AS patients was recorded in detail and the disease activity was calculated. The positive expression rates and medium fuorescence intensity (MFI) of Tim-3 in regulatory T cells were examined by fow cytometry. Statistical approaches were used to analyze the experimental data of patients and controls. Results: The Treg cells level was significantly decreased in AS patients compared to the healthy controls (5.14±0.27 vs 4.38±0.23, P = 0.032, Fig 1 A). Tim-3 expression in regulatory T cells was lower in AS patients than the HCs (63.29±2.39 vs 52.56±3.49, P = 0.013, Fig1 B). And Tim-3 MFI in regulatory T cells was significantly decreased too(1355.04±171.44 vs 859.19±105.11, P = 0.016, Fig1 C). The Treg cells ratio negatively correlated with BASDAI (r=-0395, p=0.014) and BASFI (r=-0391, p=0.015) in AS patients. However, the Tim-3 expression in the Treg cells has no correlation with diseases activity in patients. Conclusion: According to the test results, we could confirm that regulatory T cells participate in the progression of AS, and it has negative relationship with disease activity. Tim-3 can express in Treg, but whether Tim-3 can be used as a potential target for AS treatment in future need further verified. Disclosure of Interests: None declared
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2020-eular.5618
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2020
    detail.hit.zdb_id: 1481557-6
    detail.hit.zdb_id: 7090-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    THU0427 SHOULD FEBUXOSTAT-RESISTANCE BE ADDED TO CRITERIA FOR REFRACTORY GOUT? A PRELIMINARY STUDY
    BMJ ; 2020
    In:  Annals of the Rheumatic Diseases Vol. 79, No. Suppl 1 ( 2020-06), p. 452.1-452
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 79, No. Suppl 1 ( 2020-06), p. 452.1-452
    Abstract: Refractory gout manifests as recurrent flares, chronic arthritis and progressive tophaceous deposits. Febuxostat is a widely-used potent serum urate-lowering reagent, but some gout patients cannot achieve target serum uric acid (sUA) after they used this reagent. Objectives: To determine whether febuxostat-resistance should be a criterion for refractory gout, characteristics of gout patients who were resistance to febuxostat or allopurinol were compared. Methods: This study was performed from December 2015 to December 2019. Medical records of gout patients who met the 2015 gout classification criteria [1] and undertook febuxostat (febuxostat group) or allopurinol (allopurinol group) urate-lowing therapy (ULT) were assessed. Dose of ULT was adjusted till sUA was below 6 mg/dL and 5 mg/dL for patients with urate deposition. We screened gout patients who had contraindication or history of failure to normalize sUA for≥ 3 months of treatment with the maximum medically appropriate febuxostat (febuxostat-resistance) or allopurinol (allopurinol-resistance) dose as defined by physicians. Furthermore, these screened patients met the traditional criteria of refractory gout except therapeutic reaction [2] .Demography and clinical characteristics were recorded. Features between febuxostat-resistance and allopurinol-resistance patients were compared. Results: (1) Of 683 gout patients who were included, 516 and 167 of them used febuxostat or allopurinol. (2) Age (41.92±11.58 vs. 42.26±9.41 years), Male gender (97.50% vs. 97.01%), duration of gout (5.78±4.74 vs. 5.05±4.72 years) and sUA (6.30±2.50 vs. 6.67±2.14 mg/dL) were similar between febuxostat group and allopurinol group ( P 〉 0.05). (3) Dose of febuxostat or allopurinol were 47.28mg/day and 178.24mg/day. (4) Sixteen patients were febuxostat-resistance, while 6 patients were allopurinol-resistance. Prevalence rates of treatment resistance were comparable between groups (3.10% vs. 3.59%, P 〉 0.05). (5) Some parameters were different between resistance patients and non-resistance patients in both groups (Table 1, P 〈 0.05). However, characteristics of febuxostat-resistance and allopurinol-resistance patients were similar ( P 〉 0.05). Table 1 Characteristics of gout patients in febuxostat group and allopurinol group Parameters Febuxostat Group Allopurinol Group Non-resistance (n=500) Resistance (n=16) Non-resistance (n=161) Resistance (n=6) Age (year) 41.93±11.65 41.67±9.58 42.22±13.33 44.50±16.98 Male Gender (%) 97.40 100.00 96.89 100.00 BMI (kg/m 2 ) 25.44±3.46 26.22±3.47 25.86±3.97 25.60±6.42 Duration of gout (years) 5.75±4.76 7.00±3.97 * 4.96±4.73 7.75±2.62 * Flares in previous 18 months (times) 1.31±0.44 3.67±0.70 * 1.13±0.24 3.25±0.50 * Presence of Tophi (%) 23.80 100.00 * 14.90 100.00 * Presence of Complication (%) 35.8 100.00 * 31.06 100.00 * sUA (mg/dL) 6.21±2.47 9.13±1.24 * 6.42±2.32 10.15±3.55 * SCr (μmol/L) 100.67±15.03 163.96±29.41 * 96.93±22.91 133.75±31.60 * ESR (mm/L) 24.59±19.28 42.83±21.13 * 27.49±24.10 56.50±28.12 * CRP (mg/L) 18.92±18.59 28.81±23.85 * 23.12±22.63 32.28±23.64 * * P 〈 0.05 compared with non-resistance patients in the same group. BMI body mass index, sUA serum uric acid, SCr serum creatinine, ESR erythrocyte sedimentation rate, CRP C-reactive protein Conclusion: Febuxostat-resistance is a potential criterion for refractory gout, because febuxostat-resistance patients shares similar characteristics of patients with refractory gout. References: [1]Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2015;74(10):1789-1798. [2]Lawrence Edwards N, Singh JA, Troum O, et al. Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase. Rheumatology (Oxford) 2019; pii: kez017. Acknowledgments: None. Disclosure of Interests: : None declared
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2020-eular.1270
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2020
    detail.hit.zdb_id: 1481557-6
    detail.hit.zdb_id: 7090-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    AB0071 THERAPEUTIC EFFECTS OF BONE MARROW MESENCHYMAL STEM CELLS-DERIVED EXOSOMES ON OSTEOARTHRITIS
    BMJ ; 2020
    In:  Annals of the Rheumatic Diseases Vol. 79, No. Suppl 1 ( 2020-06), p. 1336.3-1336
    Details
    In: Annals of the Rheumatic Diseases, BMJ, Vol. 79, No. Suppl 1 ( 2020-06), p. 1336.3-1336
    Abstract: Mesenchymal stem cells (MSCs) have shown chondroprotective effects in clinical models of osteoarthritis (OA) [1] . Objectives: The study aimed to investigate the therapeutic potential of exosomes from human bone marrow MSCs (BM-MSCs) in alleviating OA. Methods: The anterior cruciate ligament transection (ACLT) anddestabilization of the medial meniscus (DMM) surgery were performed on the knee joints of a rat OA model, followed by intra-articular injection of BM-MSCs or their exosomes. The beneficial effects were evaluated by histological staining, OARSI scores and micro-CT. Furthermore, BM-MSCs-derived exosomes were administrated to primary human chondrocytes to observe the functional and molecular alterations. In addition, lncRNA MEG3 were investigated in chondrocytes to explore the biological contents accounting for anti-OA effects of BM-MSCs-derived exosomes. Results: Based on the observation in the rat OA model, both of BM-MSCs and BM-MSCs-derived exosomes alleviated cartilage destruction, reduced joint damage and restored the trabecular bone of OA rats. In addition, in vitro assays showed that BM-MSCs- exosomes could maintain the chondrocyte phenotype by increasing collagen type II synthesis and inhibiting IL-1β- induced senescence and apoptosis. Furthermore, exosomal lncRNA MEG3 also reduced the senescence and apoptosis of chondrocytes induced by IL-1β, indicating that lncRNA MEG3 might partially account for the anti-OA effects of BM-MSC exosomes. Conclusion: The exosomes from BM-MSCs exerted beneficial therapeutic effects on OA by reducing the senescence and apoptosis of chondrocytes, suggesting that MSCs-derived exosomes might provide a candidate therapy for OA treatment. References: [1]Mckinney J M, Doan T N, Wang L, et al. Therapeutic efficacy of intra-articular delivery of encapsulated human mesenchymal stem cells on early stage osteoarthritis[J] . Eur Cell Mater, 2019, 37: 42-59. Disclosure of Interests: None declared
    Type of Medium: Online Resource
    ISSN: 0003-4967 , 1468-2060
    URL: Article
    DOI: 10.1136/annrheumdis-2020-eular.6040
    RVK:
    XA 10000
    Language: English
    Publisher: BMJ
    Publication Date: 2020
    detail.hit.zdb_id: 1481557-6
    detail.hit.zdb_id: 7090-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...